Adial Pharmaceuticals

Update in progress

ADIL (NasdaqCM)

Adial Pharmaceuticals, Inc. is a clinical‑stage biopharmaceutical company focused on developing therapies for addiction and related disorders. Its lead candidate, AD04, is a serotonin-3 antagonist being evaluated in Phase 3 for alcohol use disorder. The company is also advancing drug candidates aimed at non-opioid pain reduction and other conditions. Founded in 2010, it is based in Glen Allen, Virginia.